Shanghai Pharmaceuticals Holding (601607.SH): The listing application for Lacosamide API has been approved.
Connecting global capital markets
Announcement: Shanghai Pharmaceuticals Holding (601607.SH) announced that its wholly-owned subsidiary Shangyao Kangli (Changzhou) Pharmaceuticals Co., Ltd. ("Shangyao Kangli") has received the "Chemical Raw Material Drug Market Application Approval Notice" (Notice No.: 2023YS00679) issued by the State Drug Administration ("National Drug Administration") for its drug Lakaosha'an. The drug has been approved for production.
Related Articles
"The 'Chinese Choice' for Global SiC Core Customers: Why TIANYU SEMI (02658)?"
The People's Bank of China has increased its gold holdings for the 15th consecutive month.
Guosen: RWA welcomes the era of strict supervision.
"The 'Chinese Choice' for Global SiC Core Customers: Why TIANYU SEMI (02658)?"
The People's Bank of China has increased its gold holdings for the 15th consecutive month.
Guosen: RWA welcomes the era of strict supervision.
RECOMMEND
Nine Companies With Market Value Over RMB 100 Billion Awaiting, Hong Kong IPO Boom Continues Into 2026
07/02/2026
Hong Kong IPO Cornerstone Investments Surge: HKD 18.52 Billion In First Month, Up More Than 13 Times Year‑On‑Year
07/02/2026
Over 400 Companies Lined Up For Hong Kong IPOs; HKEX Says Market Can Absorb
07/02/2026
